Adam S. Kittai

机构：Icahn School of Medicine at Mount Sinai · ORCID：0000-0002-4891-6144

发表论文 203 篇 · 总被引 1907 次 · h-index 21

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 27)
• Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment. (2025 · Blood · 被引 6)
• PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia (2025 · Blood Cancer Discovery · 被引 2)
• Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL (2025 · Blood · 被引 1)
• Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia (2025 · Blood · 被引 1)
• Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22 (2026)